Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02410356 · ClinicalTrials.gov registry record · Phase 3
Study to Assess Safety and Tolerability in Adults With Growth Hormone-Deficiency (GHD)
A Phase 3 study, sponsored by Teva Branded Pharmaceutical Products R&D.
- Terminated
- Registry status
- Phase 3
- Development phase
- 34
- Enrollment target
NCT02410356 is a Phase 3 study that was terminated before completion, run by Teva Branded Pharmaceutical Products R&D. The registered enrollment target is 34 participants.
The verdict
NCT02410356, a Phase 3 study, was terminated before completion, sponsored by Teva Branded Pharmaceutical Products R&D.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 34 participants
- Enrollment target
Study Summary
This study assesses the safety and tolerability of weekly TV-1106 compared to daily rhGH in adults with GHD who have previously been treated with rhGH.
Interventions
- DRUG TV-1106
- DRUG dGH
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 34 participants |
| Start Date | 2015-04-30 |
| Est. Completion | 2016-04-30 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02410356
The ClinicalTrials.gov registry entry for NCT02410356 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 34 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Teva Branded Pharmaceutical Products R&D, which has 167 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which TV-1106 is the first listed.
NCT02410356 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02410356 about?
NCT02410356 is a clinical study titled "Study to Assess Safety and Tolerability in Adults With Growth Hormone-Deficiency (GHD)". This study assesses the safety and tolerability of weekly TV-1106 compared to daily rhGH in adults with GHD who have previously been treated with rhGH.
What is the current status of trial NCT02410356?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 34 participants. The study started on 2015-04-30. Estimated completion is 2016-04-30.
What interventions are being tested in trial NCT02410356?
The interventions under investigation include: TV-1106 (DRUG), dGH (DRUG).
Who is sponsoring clinical trial NCT02410356?
This trial is sponsored by Teva Branded Pharmaceutical Products R&D, which has 167 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.